N6-methyladenosine modification and post-translational modification of epithelial-mesenchymal transition in colorectal cancer

被引:0
|
作者
Wang, Yingnan [1 ]
Chen, Yufan [1 ]
Zhao, Miaomiao [1 ]
机构
[1] Zhejiang Univ, Canc Ctr, Stomatol Hosp, Zhejiang Prov Clin Res Ctr Oral Dis,Sch Stomatol,S, Hangzhou 310000, Peoples R China
关键词
Epithelial-mesenchymal transition (EMT); Epigenetics; Post-translational modification (PTM); N6-methyladenosine (M6A); Colorectal cancer; Tumorigenesis; Metastasis; Immunotherapy; STEM-CELLS; EMT; IMMUNE; PROGRESSION; EZH2; METASTASIS; ACTIVATION; EXPRESSION; INHIBITOR; PATHWAY;
D O I
10.1007/s12672-024-01048-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer is a leading cause of cancer-related mortality worldwide. Traditionally, colorectal cancer has been recognized as a disease caused by genetic mutations. However, recent studies have revealed the significant role of epigenetic alterations in the progression of colorectal cancer. Epithelial-mesenchymal transition, a critical step in cancer cell metastasis, has been found to be closely associated with the tumor microenvironment and immune factors, thereby playing a crucial role in many kinds of biological behaviors of cancers. In this review, we explored the impact of N6-methyladenosine and post-translational modifications (like methylation, acetylation, ubiquitination, SUMOylation, glycosylation, etc.) on the process of epithelial-mesenchymal transition in colorectal cancer and the epigenetic regulation for the transcription factors and pathways correlated to epithelial-mesenchymal transition. Furthermore, we emphasized that the complex regulation of epithelial-mesenchymal transition by epigenetics can provide new strategies for overcoming drug resistance and improving treatment outcomes. This review aims to provide important scientific evidence for the prevention and treatment of colorectal cancer based on epigenetic modifications.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] New sights in cancer: Component and function of N6-methyladenosine modification
    Hu, Yiyang
    Wang, Sumin
    Liu, Jiao
    Huang, Yu
    Gong, Chunli
    Liu, Jingjing
    Xiao, Yufeng
    Yang, Shiming
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 122
  • [32] Emerging Regulatory Mechanisms of N6-Methyladenosine Modification in Cancer Metastasis
    Jing Zhao
    Hao Xu
    Yinghan Su
    Junjie Pan
    Sunzhe Xie
    Jianfeng Xu
    Lunxiu Qin
    Phenomics, 2023, 3 : 83 - 100
  • [33] Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer
    Zhixian Liang
    Reilly LKidwell
    Haijing Deng
    Qi Xie
    Cancer Biology & Medicine, 2020, 17 (01) : 9 - 19
  • [34] N6-Methyladenosine methylation modification in breast cancer: current insights
    Zhang, Guangwen
    Cheng, Chen
    Wang, Xinle
    Wang, Shiming
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [35] Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer
    Zhixian Liang
    Reilly L.Kidwell
    Haijing Deng
    Qi Xie
    Cancer Biology & Medicine , 2020, (01) : 9 - 19
  • [36] Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer
    Zhang, Yuhong
    Ling, Yufeng
    Zhou, Ying
    Shi, Xiu
    Shen, Fangrong
    Zhou, Jinhua
    Chen, Youguo
    Yang, Fan
    Gu, Yanzheng
    Wang, Juan
    CANCER CONTROL, 2024, 31
  • [37] Mechanism of N6-methyladenosine modification and its emerging role in cancer
    Zhang, Sicong
    PHARMACOLOGY & THERAPEUTICS, 2018, 189 : 173 - 183
  • [38] Importance of N6-methyladenosine RNA modification in lung cancer (Review)
    Wang, Yueyang
    Su, Xiaoming
    Zhao, Mingyao
    Xu, Mingchen
    Chen, Yueqi
    Li, Zhengyi
    Zhuang, Wenyue
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (06)
  • [39] N6-methyladenosine (m6A) RNA modification in human cancer
    Huo, Fu-Chun
    Zhu, Zhi-Man
    Pei, Dong-Sheng
    CELL PROLIFERATION, 2020, 53 (11)
  • [40] The role of N6-methyladenosine modification in tumor angiogenesis
    Qin, Lifei
    Zeng, Xinya
    Qiu, Xinze
    Chen, Xingmei
    Liu, Shiquan
    FRONTIERS IN ONCOLOGY, 2024, 14